Stay updated on Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Sign up to get notified when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.

Latest updates to the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.1%

- Check22 days agoChange DetectedA notice was added about NIH website updates and the use of “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference0.5%

- Check29 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.7.2 instead of v3.7.1.SummaryDifference0.1%

- Check36 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check57 days agoChange DetectedA new revision entry v3.7.0 has been added to the record history, and the previous entry v3.6.6 has been removed. This updates the page’s version history to reflect the latest administrative change.SummaryDifference0.1%

- Check78 days agoChange DetectedAn additional revision entry v3.6.6 was added to the record history. The previous v3.6.5 entry was removed, reflecting an update to the page's version history.SummaryDifference0.1%

Stay in the know with updates to Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab After Radiation in Stage 3 NSCLC – Clinical Trial page.